Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775271 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2GRM8GRM4CFTRSLC6A2 | |
| SCHEMBL3869951 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2GRM8GRM4CFTRSLC6A2 | |
| Hydrochloric Acid SCHEMBL6773732 | 0.98 | SMN1; SMN2 (0.47) | SMN1; SMN2GRM8GRM4CFTRSLC6A2 | |
| Hydrochloric Acid SCHEMBL27645555 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2GRM8GRM4CFTRSLC6A2 | |
| SCHEMBL25287082 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2GRM8GRM4CFTRSLC6A2 | |
| SCHEMBL31038319 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2GRM8GRM4CFTRSLC6A2 | |
| SCHEMBL235125 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2GRM8GRM4CFTRSLC6A2 | |
| SCHEMBL29852444 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2GRM8GRM4CFTRSLC6A2 | |
| SCHEMBL20213798 | 0.81 | TBXAS1 (0.49) | SMN1; SMN2GRM8GRM4CFTRSLC6A2 | |
| SCHEMBL7506734 | 0.81 | ALDH1A1 (0.45) | SMN1; SMN2KDM4EROCK2ROCK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1932852-A1 | Novel taxane related peptides and uses thereof | Campiani, Giuseppe (IT) | 2008-06-18 | — | — | EP | claimed |
| EP-0810994-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0810994-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1997-12-10 | — | — | EP | claimed |
| EP-1932852-A1 | Novel taxane related peptides and uses thereof | Campiani, Giuseppe (IT) | 2008-06-18 | — | — | EP | disclosed |
| EP-1165543-B1 | PROCESS FOR PREPARING S-(R*,S*)] -$g(b) - 1- 1-OXO-3- (4-PIPERIDINYL) PROPYL] -3-PIPERIDINYL] CARBONYL] AMINO] -3- PYRIDINEPROPANOIC ACID AND DERIVATIVES | ORTHO MCNEIL PHARM INC (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6515130-B1 | The invention relates to a process of preparing (S-(R*,S*))-beta -(((1-(1-oxo-3-(4-piperidinyl)propyl)-3-piperidinyl) carbonyl)amino)-3-pyridinepropanoic acid derivatives represented by the antagonists of the platelet fibrinogen | COHEN JUDITH H (US) | 2003-02-04 | — | — | US | disclosed |
| US-20020137937-A1 | Process for preparing [S- (R*, S*) ] -beta- [ [ [1- [1-oxo-3- (4-piperidinyl) propyl] -3-piperidinyl] carbonyl]amino] -3-pyridinepropanoic acid and derivatives | COHEN JUDITH H (US) | 2002-09-26 | — | — | US | disclosed |
| EP-0946165-A4 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-0946165-A1 | INTEGRIN ANTAGONISTS | Merck & Co., Inc. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998018460-A1 | INTEGRIN ANTAGONISTS | MERCK & CO., INC. (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137937-A1 | Process for preparing [S- (R*, S*) ] -beta- [ [ [1- [1-oxo-3- (4-piperidinyl) propyl] -3-piperidinyl] carbonyl]amino] -3-pyridinepropanoic acid and derivatives | GRHPR, SUCNR1, GABARAPL1 | SMN1; SMN2 1351/4885GRM8 3686/4885GRM4 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.